<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818868</url>
  </required_header>
  <id_info>
    <org_study_id>2157</org_study_id>
    <nct_id>NCT02818868</nct_id>
  </id_info>
  <brief_title>Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial</brief_title>
  <acronym>ALVO</acronym>
  <official_title>Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyogo College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyogo College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the clinical events of the patients with acute
      cerebral large vessel occlusion or stenosis and atrial fibrillation, treated by apixaban
      within 14 days after onset. This is the observational study that patients will be made the
      registration at the timing of both retrospective period and prospective period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four novel oral anticoagulants (NOACs) have been released to the market ahead of any county
      in the world. However, no information is available on the clinical results of NOACS and their
      secondary preventive effects in Japanese population.

      Medical care for acute-phase stroke is constantly advancing. Specifically, in addition to
      thrombolytic activator tissue plasminogen activator (t-PA), advancement of endovascular
      thrombectomy has made it possible to treat patients who would not have been saved otherwise.
      In Japan, cerebrovascular accident had been the third leading cause of death, but now has
      dropped to the forth thanks to wide use of various treatments. Nevertheless, patients often
      suffer from severe sequelae after stroke, even if they survive. In other words, major
      challenge in the treatment of stroke is not only to save the patients but also to improve the
      long-term prognosis.

      In large-scale study, NOAC showed an equal to or greater efficacy in preventing recurrence of
      stroke compared with warfarin and significantly reduced the incidence of bleeding
      complications. Furthermore, Aristotle trial comparing apixaban vs. warfarin demonstrated that
      apixaban provided a significant prevention of stroke recurrence as well as significant
      reduction of bleeding complications and deaths.

      Heparin and warfarin had been used as the mainstream agents for the prevention of recurrence
      after hyperacute phase treatment.However, Aristotle trial showed that there was a significant
      difference in thromboembolic events between apixaban treatment (1.27 %/year) and warfarin
      (1.60%/year) (RR 0.79, p&lt;0.01). Also, major bleeding events were less frequent in the
      patients with apixaban treatment (2.13 %/year) compared to those with warfarin (3.09%/year)
      (RR 0.69, p&lt;0.001). This study is conducted on the basis of expectation that the use of
      apixaban in place of traditional warfarin therapy further improve prognosis and reduce
      bleeding complications in Japanese patients with acute occlusion of major cerebral artery.
      Additionally, the study will analyze the correlation of the use of apixaban with the
      prognosis and the incidence of bleeding/ischemic events in patients with intracranial artery
      stenosis greater than 50% and with atrial fibrillation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>90 days after disease onset</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>90 days after disease onset</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>90 days after disease onset</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale</measure>
    <time_frame>90 days (±10 days) and 365days（±10 days） after disease onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days and 365day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic event</measure>
    <time_frame>30 days and 365day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding event</measure>
    <time_frame>30 days and 365day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant bleeding (ISTH)</measure>
    <time_frame>30 days 90 days (±10 days) and 365day</time_frame>
    <description>scale bleeding events Among the major bleeding , according to the society and hemostasis of international thrombosis (ISTH) bleeding criteria , those that fall under any of the following criteria .
lethal bleeding
important sites or symptomatic bleeding of organs ( intracranial, bone marrow , in the eye , retroperitoneal , intra-articular , or heart sac bleeding , or muscle hemorrhage with a compartment syndrome )
hemoglobin value has decreased 2 g / dL or more bleeding , whole blood transfusion or red blood cells ( more than 2 units) bleeding that required blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>0 days, 90 days and 365days</time_frame>
    <description>scale
Symptomatic intracranial hemorrhage (SICH): new intracranial hemorrhage , which corresponds to one of the following:
1) which compared to the worse just before the NIHSS, admitted the deterioration of more than 4 points 2 ) that recognized the deterioration of two or more points in one of the NIHSS category 3 ) intubation / outside decompression / drainage detention or other things that led to the expensive medical / surgical intervention 4 ) it is not a worsening due to other causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke and systemic embolism</measure>
    <time_frame>30 days, 90 days and 365days</time_frame>
    <description>systemic embolism defined as an event in which the cases with embolism of extremity arteries, intestinal arteries, renal arteries, etc., accompanied by symptoms of local organs.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Ischemic Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixisaban</intervention_name>
    <other_name>eliquis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any adult patient with acute stroke who treated with apixaban.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 20 years and older with acute stroke and treated with oral apixaban within 14
             days after onset.

          2. Patients who are hospitalized in a period from Oct 1, 2014 to Feb 28, 2018

          3. Patients with acute cerebral large vessel occlusion or stenosis (&gt; 50%)

          4. Patients with non-valvular atrial fibrillation

          5. Patients who are not confirmed ICH by MRI or CT within 24 hours after r-tPA infusion.

        Exclusion Criteria:

          1. Patients who are considered to be ineligible for the study participation by the
             investigator.

          2. Patients who are pregnant or potentially pregnant.

          3. Patients who have a history of hypersensitivity to apixaban

          4. Patients with hepatic disease having coagulation disorder and clinically important
             bleeding risk

          5. Patients with renal failure (creatinine clearance &lt; 15 mL/min) 6）Patients with Active
             pathological bleeding including intracranial bleeding of any type
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Unhid Kazutaka, MD</last_name>
    <phone>+810798456458</phone>
    <phone_ext>84212</phone_ext>
    <email>kuchidans@yahoo.co.jp</email>
  </overall_contact>
  <results_reference>
    <citation>Hirano T, Sasaki M, Mori E, Minematsu K, Nakagawara J, Yamaguchi T; Japan Alteplase Clinical Trial II Group. Residual vessel length on magnetic resonance angiography identifies poor responders to alteplase in acute middle cerebral artery occlusion patients: exploratory analysis of the Japan Alteplase Clinical Trial II. Stroke. 2010 Dec;41(12):2828-33. doi: 10.1161/STROKEAHA.110.594333. Epub 2010 Oct 28.</citation>
    <PMID>21030700</PMID>
  </results_reference>
  <results_reference>
    <citation>Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007 Mar;38(3):967-73. Epub 2007 Feb 1.</citation>
    <PMID>17272772</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T; MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007 Oct;38(10):2633-9. Epub 2007 Aug 16.</citation>
    <PMID>17702958</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999 Dec;30(12):2598-605.</citation>
    <PMID>10582984</PMID>
  </results_reference>
  <results_reference>
    <citation>IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007 Jul;38(7):2127-35. Epub 2007 May 24.</citation>
    <PMID>17525387</PMID>
  </results_reference>
  <results_reference>
    <citation>Cass AS, Cass BP, Veeraraghavan K. Immediate exploration of the unilateral acute scrotum in young male subjects. J Urol. 1980 Dec;124(6):829-32.</citation>
    <PMID>7441833</PMID>
  </results_reference>
  <results_reference>
    <citation>Kelly ME, Furlan AJ, Fiorella D. Recanalization of an acute middle cerebral artery occlusion using a self-expanding, reconstrainable, intracranial microstent as a temporary endovascular bypass. Stroke. 2008 Jun;39(6):1770-3. doi: 10.1161/STROKEAHA.107.506212. Epub 2008 Apr 3.</citation>
    <PMID>18388338</PMID>
  </results_reference>
  <results_reference>
    <citation>Mocco J, Hanel RA, Sharma J, Hauck EF, Snyder KV, Natarajan SK, Linfante I, Siddiqui AH, Hopkins LN, Boulos AS, Levy EI. Use of a vascular reconstruction device to salvage acute ischemic occlusions refractory to traditional endovascular recanalization methods. J Neurosurg. 2010 Mar;112(3):557-62. doi: 10.3171/2009.8.JNS09231.</citation>
    <PMID>19764826</PMID>
  </results_reference>
  <results_reference>
    <citation>Flint AC, Duckwiler GR, Budzik RF, Liebeskind DS, Smith WS; MERCI and Multi MERCI Writing Committee. Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke. 2007 Apr;38(4):1274-80. Epub 2007 Mar 1.</citation>
    <PMID>17332445</PMID>
  </results_reference>
  <results_reference>
    <citation>Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009 Aug;40(8):2761-8. doi: 10.1161/STROKEAHA.108.544957. Epub 2009 Jul 9.</citation>
    <PMID>19590057</PMID>
  </results_reference>
  <results_reference>
    <citation>Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO; SWIFT Trialists. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012 Oct 6;380(9849):1241-9. doi: 10.1016/S0140-6736(12)61384-1. Epub 2012 Aug 26.</citation>
    <PMID>22932715</PMID>
  </results_reference>
  <results_reference>
    <citation>Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS; TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012 Oct 6;380(9849):1231-40. doi: 10.1016/S0140-6736(12)61299-9. Epub 2012 Aug 26. Erratum in: Lancet. 2012 Oct 6;380(9849):1230.</citation>
    <PMID>22932714</PMID>
  </results_reference>
  <results_reference>
    <citation>Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 7;368(10):893-903. doi: 10.1056/NEJMoa1214300. Epub 2013 Feb 7. Erratum in: N Engl J Med. 2013 Mar 28;368(13):1265.</citation>
    <PMID>23390923</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoshimura S, Sakai N, Okada Y, Kitagawa K, Kimura K, Tanahashi N, Hyogo T, Yamagami H, Egashira Y; Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry Investigators. Efficacy of endovascular treatment for acute cerebral large-vessel occlusion: analysis of nationwide prospective registry. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1183-90. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.014. Epub 2014 Jan 11.</citation>
    <PMID>24424332</PMID>
  </results_reference>
  <results_reference>
    <citation>Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000 May 13;355(9216):1670-4. Erratum in: Lancet 2000 Jun 17;355(9221):2170.</citation>
    <PMID>10905241</PMID>
  </results_reference>
  <results_reference>
    <citation>Nezu T, Koga M, Nakagawara J, Shiokawa Y, Yamagami H, Furui E, Kimura K, Hasegawa Y, Okada Y, Okuda S, Kario K, Naganuma M, Maeda K, Minematsu K, Toyoda K. Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry. Stroke. 2011 Aug;42(8):2196-200. doi: 10.1161/STROKEAHA.111.614404. Epub 2011 Jun 30.</citation>
    <PMID>21719764</PMID>
  </results_reference>
  <results_reference>
    <citation>Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T; Japan Alteplase Clinical Trial II Group. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke. 2010 Mar;41(3):461-5. doi: 10.1161/STROKEAHA.109.573477. Epub 2010 Jan 14.</citation>
    <PMID>20075341</PMID>
  </results_reference>
  <results_reference>
    <citation>Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, Marks MP, Prabhakaran S, Kallmes DF, Fitzsimmons BF, Mocco J, Wardlaw JM, Barnwell SL, Jovin TG, Linfante I, Siddiqui AH, Alexander MJ, Hirsch JA, Wintermark M, Albers G, Woo HH, Heck DV, Lev M, Aviv R, Hacke W, Warach S, Broderick J, Derdeyn CP, Furlan A, Nogueira RG, Yavagal DR, Goyal M, Demchuk AM, Bendszus M, Liebeskind DS; Cerebral Angiographic Revascularization Grading (CARG) Collaborators; STIR Revascularization working group; STIR Thrombolysis in Cerebral Infarction (TICI) Task Force. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke. 2013 Sep;44(9):2650-63. doi: 10.1161/STROKEAHA.113.001972. Epub 2013 Aug 6.</citation>
    <PMID>23920012</PMID>
  </results_reference>
  <results_reference>
    <citation>Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27;369(9558):275-82. Erratum in: Lancet. 2007 Mar 10;369(9564):826.</citation>
    <PMID>17258667</PMID>
  </results_reference>
  <results_reference>
    <citation>van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604-7.</citation>
    <PMID>3363593</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

